News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Hapoalim Securities Expects Eli Lilly and Company To Acquire Amylin Pharmaceuticals, Inc. Post Approval Of AMLN’s Bydureon
June 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Benzinga.com -- Analyst Jon LeCroy of Hapoalim Securities reiterates his "buy" rating on Amylin Pharmaceuticals (NASDAQ: AMLN). The target price for AMLN is set to $22.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Eli Lilly and Company
MORE ON THIS TOPIC
Drug Development
CRO Boom in APAC region, With China at the Forefront
November 19, 2025
·
5 min read
·
Jennifer Smith-Parker
Mergers & acquisitions
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
November 19, 2025
·
3 min read
·
Tristan Manalac
Podcast
Billions More in M&A, Another Bidding War and More FDA Drama
November 19, 2025
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions
November 19, 2025
·
9 min read
·
Tristan Manalac
